Tagged Articles

Tradjenta 16 articles

Weight loss from newer diabetes drugs may come at steep price

Newer classes of type 2 diabetes drugs can help patients lose weight, but that benefit may come at a high price. Being overweight is a risk factor for type 2 diabetes. Patients diagnosed with the chronic disease are generally advised to adopt a healthy diet and get regular exercise to help keep their blood sugar levels in check. Uncontrolled diabetes can increase the risk of serious health problems including heart disease, kidney disease, some cancers, blindness, neuropathy, and dementia. Losing weight through diet and exercise can help diabetics better manage and, in some cases, fend off the disease. However, reaching ... Read More

FDA approves new combination Type 2 diabetes drug Glyxambi

The Food and Drug Administration (FDA) has approved Glyxambi, a new treatment for Type 2 diabetes that combines two previously approved diabetes drugs, empagliflozin (marketed as Jardiance) and linagliptin (sold as Tradjenta). Glyxambi is the first and only diabetes treatment in the U.S. to combine the dual mechanisms of a sodium glucose co-transporter-2 (SGLT2) inhibitor (Jardiance) and a dipeptidyl peptidase-4 (DPP-4) inhibitor (Tradjenta) in a tablet, which is taken once every morning. SGLT2 inhibitors work by removing glucose through the urine by blocking blood glucose re-absorption in the kidneys. DPP-4 inhibitors work by increasing hormones that stimulate the pancreas to ... Read More

Long-term pancreatic cancer risks with class of type 2 diabetes drugs still unknown

Drugs in a class of Type 2 diabetes medications known as DPP-4 inhibitors may not increase the short-term risk of pancreatic cancer, but the long-term risks are still unknown, according to a new study published in the journal Diabetes, Obesity and Metabolism. The study was conducted by researchers with the University of North Carolina (UNC) Gillings School of Global Public Health and the UNC School of medicine, and focused on pancreatic cancer risks with DPP-4 inhibitors such as Januvia and Janumet (sitagliptin), and Tradjenta (linagliptin). DPP-4 inhibitors were first marketed in the United States in 2006 and have since become ... Read More

Newer type 2 diabetes drugs carry serious side effects, pancreatic cancer risks

The newest classes of type 2 diabetes drugs may help diabetics manage their disease, but it can come at a great price. Diabetes drugs known as GLP-1, DPP-4, and SLGT2 have been associated with serious side effects including acute pancreatitis, pancreatic cancer, thyroid cancer, urinary tract infections, gastrointestinal issues, and renal and gallbladder problems, according to AdverseEvents (AE), a company that analyzes post-market side effects data. According to DrugWatch.com, Glucagon-like peptide-1 receptor (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors both affect levels of the incretin hormone, which helps to control blood sugar. Sodium-glucose co-transporter 2 (SGLT2) inhibitors (glucuretics) block glucose reabsorption ... Read More

Some diabetes drugs may be linked to more serious side effects than initially thought

Type 2 diabetes drugs known as DPP-4 inhibitors may be linked to more serious side effects than generally believed, according to an analysis from AdverseEvents. AdverseEvents, a health care informatics company, analyzed data on 11 of the newer type 2 diabetes drugs to conclude which were the safest and which may need closer watch. The drugs included in the study involved GLP-1 receptor agonists, such as Bydureon, Byetta, and Victoza, and DPP-4 inhibitors, such as Janumet, Januvia, Tradjenta and Nesina. AdverseEvents examined data from the Food and Drug Administration’s (FDA) Adverse Event Reporting System, FAERS, and then identified suspect cases ... Read More

Alabama residents with Type 2 diabetes sought for long-term study on medication effectiveness

Researchers at the University of Alabama at Birmingham (UAB) are enrolling participants in an ongoing study on the long-term benefits and side effects with certain combinations of drugs to treat type 2 diabetes. Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness, or GRADE, is a national study that is being conducted at UAB and 36 other sites across the country. Enrollment began in June 2013, but more participants are being sought. More than 5,000 people will be enrolled in the study. Subjects must have type 2 diabetes that was diagnosed within the past five years and should not be on ... Read More

Clinical trials to begin on novel new type 2 diabetes drug

Zydus Cadila Healthcare has been given approval by the Food and Drug Administration (FDA) to begin phase I clinical trials of ZYDPLA1, a novel next generation orally active small molecule DPP-4 inhibitor to treat type 2 diabetes. ZYDPLA1 is a New Chemical Entity (NCE), a classification given to a drug that contains no active functioning group that has been approved by the FDA in any other application. The drug was discovered and developed by the Zydus Research Center. It is a novel compound in the Gliptin class of diabetes medications, also known as DPP-4 inhibitors. ZYDPLA1 works by blocking the enzyme ... Read More

New pancreatitis warnings added to diabetes drugs Tradjenta, Jentadueto

The safety labels for the type 2 diabetes drugs Tradjenta (linagliptin tablets) and Jentadueto (linagliptin and metformin) have been updated to include a warning that using the drugs may cause a type of pancreas inflammation known as pancreatitis, which in some cases can be fatal. Tradjenta and Jentadueto, which both include the active ingredient linagliptin, are in a class of oral medications known as dipeptidyl peptidase 4, or DPP-4 inhibitors. Other drugs in this class include Januvia and Onglyza. The warnings state that there have been post-marketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking linagliptin. Doctors who ... Read More

Diabetes drug Tradjenta linked to acute pancreatitis, fatal pancreatitis

The safety label for the type 2 diabetes treatment Tradjenta (linagliptin) has been updated to warn that there have been reports of acute pancreatitis, including fatal pancreatitis, in patients taking the medication. Doctors and patients are advised to take special note of potential signs and symptoms of pancreatitis, and if the condition is suspected, to discontinue Tradjenta and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at an increased risk for developing the condition while using the drug. Tradjenta is an oral medication that is designed to reduce blood sugar levels in patients with ... Read More

Type 2 diabetes drug does not reduce risk of heart attack, stroke, death

Diabetes drug Onglyza (saxagliptin) does not reduce the risk of heart attacks, strokes or death from cardiovascular causes compared to a placebo, drug makers Bristol Myers Squibb and AstraZeneca said. The companies had conducted clinical trials to determine if the Type 2 diabetes treatment could help reduce the risk of non-fatal heart attacks and ischemic strokes and death from cardiovascular problems as well as lower blood glucose levels. Onglyza did not perform better than a placebo; however, it was not inferior to the placebo either. The clinical trials involved 16,500 people with diabetes as well as a history of heart ... Read More